Skip to main content

Table 1 Patient data, first line chemotherapy and laboratory results of the whole patient collective, grouped into the patients matching our oligometastatic disease (OMD) criteria and those who do not

From: Proposal for a definition of "Oligometastatic disease in pancreatic cancer"

 Oligometastatic disease (OMD) n = 10No oligometastatic disease (noOMD) n = 118Mann-Whitney U Test (p-value)
Sex
 Male (%)7 (70)73 (61) 
 Female (%)3 (30)47 (39) 
Age upon diagnosis, median (minimum; maximum)65 (53;89)66 (30;84)0.945
Primary tumor: size [cm2], median (minimum; maximum)14.5 (4.4;21.6)12.0 (0.8;68.4)0.758
Primary tumor: max. diameter [cm], median (minimum; maximum)4.1 (2.4;9.0)4.0 (1.0;10.4)0.348
Primary tumor: Location
 Head, n (%)2 (20.0)53 (46.5) 
 Body, n (%)4 (40.0)17 (15.8) 
 Tail, n (%)4 (40.0)42 (37.7) 
Chemo: First line
 None, n (%)0 (0)17 (14.2) 
 Gemcitabine, n (%)3 (30.0)38 (31.7) 
 Gemcitabine + Erlotinib, n (%)2 (20.0)13 (10.8) 
 Gemcitabine + nab-Paclitaxel, n (%)2 (20.0)19 (15.8) 
 FOLFIRINOX, n (%)0 (0)4 (3.3) 
 5-FU, n (%)0 (0)2 (1.7) 
 Gemcitabine + Afatinib, n (%)1 (10.0)12 (10.0) 
 Capecitabin + Erlotinib, n (%)0 (0)1 (0.8) 
 Ibrutinib/Placebo + nab-Paclitaxel + Gemcitabine, n (%)1 (10.0)8 (6.7) 
 NAPOLI, n (%)0 (0)1 (0.8) 
 Capecitabine, n (%)1 (10.0)2 (1.7) 
 FOLFOX, n (%)0 (0)1 (0.8) 
 Gemcitabine + nab-Paclitaxel + Afatinib, n (%)0 (0)2 (1.7) 
Bilirubin level [mg/dL] BL, median (minimum; maximum)0.3 (0.2;1.7)0.6 (0.2;14.2)0.157
LDH [U/L] BL, median (minimum; maximum)209 (179;393)230 (13;1870)0.439
CRP [mg/L] BL, median (minimum; maximum)28 (4;65)11 (1;348)0.498
CA 19–9 [U/mL] BL, median (minimum; maximum)35 (2;885)978 (1;938,670)0.003
CEA [μg/L] BL, median (minimum; maximum)4 (2;80)11 (0;13,006)0.140